| 08/18/2026 4:29 PM | NextCure (1661059) Filer | Form S-4 Registration statement under Securities Act of 1933 | |
| 08/14/2026 8:33 PM | ADAR1 Capital Management, LLC (1940272) Filed by NextCure (1661059) Subject | Form SCHEDULE 13G | |
| 08/14/2026 7:57 PM | Ikarian Capital, LLC (1778253) Filed by NextCure (1661059) Subject | Form SCHEDULE 13G/A | |
| 08/14/2026 12:09 PM | NextCure (1661059) Subject Squadron Capital Management LLC (2050709) Filed by | Form SCHEDULE 13G/A | |
| 08/13/2026 3:05 PM | Affinity Asset Advisors, LLC (1773195) Filed by NextCure (1661059) Subject | Form SCHEDULE 13G/A | |
| 08/12/2026 11:06 AM | Adage Capital Management, L.P. (1535978) Filed by NextCure (1661059) Subject | Form SCHEDULE 13G | |
| 08/12/2026 10:35 AM | Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. (2082506) Reporting NextCure (1661059) Issuer Ren Jinsheng (1455397) Reporting Simcere Pharmaceutical Group Ltd (2082516) Reporting Simcere Zaiming Pharmaceutical Co., Ltd. (2088064) Reporting Simcere Zaiming, Inc. (2080252) Reporting Tang Renhong (2088593) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/10/2026 3:01 PM | NextCure (1661059) Subject | Form 425 | |
| 08/06/2026 3:16 PM | NextCure (1661059) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/04/2026 6:30 AM | NextCure (1661059) Subject | Form 425 | |
| 08/03/2026 4:53 PM | ADAR1 Capital Management, LLC (1940272) Reporting NextCure (1661059) Issuer Schneeberger Daniel (1861120) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for NXTC and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.
|
| 07/29/2026 5:18 PM | ADAR1 Capital Management, LLC (1940272) Reporting NextCure (1661059) Issuer Schneeberger Daniel (1861120) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/16/2026 4:28 PM | NextCure (1661059) Subject | Form 425 | |
| 07/14/2026 6:00 AM | NextCure (1661059) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/14/2026 6:02 AM | NextCure (1661059) Subject | Form 425 | |
| 06/25/2026 7:01 AM | NextCure (1661059) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/22/2026 3:14 PM | Houston John G (1753537) Reporting NextCure (1661059) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:14 PM | KABAKOFF DAVID S (1024008) Reporting NextCure (1661059) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:14 PM | NextCure (1661059) Issuer Webster Stephen W (1438421) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:14 PM | Borgman Anne Elizabeth (1886388) Reporting NextCure (1661059) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:15 PM | Jones Elaine V (1296907) Reporting NextCure (1661059) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:15 PM | Feigal Ellen (1758108) Reporting NextCure (1661059) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/01/2026 7:10 AM | NextCure (1661059) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/13/2026 3:42 PM | NextCure (1661059) Subject SILVERARC CAPITAL MANAGEMENT, LLC (1816307) Filed by | Form SCHEDULE 13G/A | |
| 05/07/2026 3:19 PM | NextCure (1661059) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/06/2026 8:26 PM | NextCure (1661059) Subject Simcere Zaiming, Inc. (2080252) Filed by | Form SCHEDULE 13G/A | |
| 04/24/2026 3:15 PM | NextCure (1661059) Filer | Form DEF 14A | |
| 04/24/2026 3:18 PM | NextCure (1661059) Filer | Form DEFA14A | |
| 03/05/2026 3:26 PM | NextCure (1661059) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/05/2026 3:15 PM | NextCure (1661059) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/05/2026 5:06 AM | NextCure (1661059) Subject Sofinnova Venture Partners IX, L.P. (1612133) Filed by | Form SCHEDULE 13D/A | |
| 02/17/2026 4:28 PM | Ikarian Capital, LLC (1778253) Filed by NextCure (1661059) Subject | Form SCHEDULE 13G | |
| 02/17/2026 11:00 AM | NextCure (1661059) Subject Squadron Capital Management LLC (2050709) Filed by | Form SCHEDULE 13G/A | |
| 02/12/2026 11:05 AM | NextCure (1661059) Subject SILVERARC CAPITAL MANAGEMENT, LLC (1816307) Filed by | Form SCHEDULE 13G | |
| 01/29/2026 8:33 PM | Affinity Asset Advisors, LLC (1773195) Filed by NextCure (1661059) Subject | Form SCHEDULE 13G/A | |
| 01/23/2026 6:20 AM | NextCure (1661059) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/19/2025 4:29 PM | NextCure (1661059) Filer | Form 424B5 | |
| 12/19/2025 4:31 PM | NextCure (1661059) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/11/2025 11:15 PM | NextCure (1661059) Filer | Form EFFECT | |
| 12/11/2025 3:59 PM | NextCure (1661059) Filer | Form 424B1 | |
| 12/09/2025 8:32 PM | NextCure (1661059) Filer | Form D Notice of Exempt Offering of Securities | |
The trade I’ve been waiting for since 2011 (Ad) Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply.
But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle. Watch the free video briefing and learn the No. 1 trade to leverage rising gold |
| 11/17/2025 7:20 AM | NextCure (1661059) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/05/2025 3:25 PM | NextCure (1661059) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/05/2025 3:16 PM | NextCure (1661059) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/24/2025 3:37 PM | NextCure (1661059) Subject Squadron Capital Management LLC (2050709) Filed by | Form SCHEDULE 13G | |
| 09/29/2025 3:00 PM | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. (2088064) Reporting Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. (2082506) Reporting NextCure (1661059) Issuer Ren Jinsheng (1455397) Reporting Simcere Pharmaceutical Group Ltd (2082516) Reporting Simcere Zaiming, Inc. (2080252) Reporting Tang Renhong (2088593) Reporting | Form 3/A | |